Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor

A compound having a structural of formula (I) or a pharmaceutically acceptable salt, an isomer or a solvate thereof,

• wherein,
• w is
• n=1;
• Y1, Y2 and Y3 are —C(R)2—;
• X1 is selected from CRX1, and N;
• X2 is selected from CRX2, and N;
• X3 is selected from CRX3, and N;
• each of RX1, RX2, RX3 is independently selected from H, F, Cl, Br, I, CN, OH, SH, and NH2, or each of RX1, RX2, RX3 is independently selected from a C1-6 alkyl and a C1-6 heteroalkyl which is optionally substituted by one, two, three or four R(s),
• R1 is selected from H, F, Cl, Me, CN, and CF3;
• R2 is selected from R02, OR02, and SR02;
• R02 is independently selected from a C1-4 alkyl, a C1-4 heteroalkyl, and a C3-5 cycloalkyl-(CH2)0-3—, each of which is optionally substituted by one, two, three or four R(s);
• R3 is selected from a C1-6 alkyl, a C1-6 heteroalkyl, a C2-4 alkynyl, a 3- to 7-membered cycloalkyl, a 3- to 7-membered cycloalkyl-L-, a 3- to 7-membered heterocycloalkyl, and a 3- to 7-membered heterocycloalkyl-L-, each of which is optionally substituted by one, two, three or four R(s);
• L is selected from —O—, —S—, —C(═O)—, —S(═O)2—, and —S(═O)—, or L is selected from NH, a C1-4 alkyl, and a C1-4 heteroalkyl, each of which is optionally substituted by one, two, three or four R(s);
• the “hetero” represents a heteroatom or a hetero-atomic group, which is selected from —C(═O)NH—, —NH—, —O—, —S—, N, ═O, ═S, —C(═O)O—, —C(═O)—, —C(═S)—, —S(═O)—, and —S(═O)2—;
• the number of the heteroatom or the hetero-atomic group is independently selected from 0, 1, 2, and 3;
• R is selected from H, F, Cl, Br, I, OH, and CN, or R is selected from NH2, a C1-4 alkyl, a C1-4 heteroalkyl, a 3- to 7-membered cycloalkyl, and a 3- to 7-membered heterocycloalkyl which is optionally substituted by one, two, three or four R′(s);
• R′ is selected from F, Cl, Br, I, CN, OH, NH2, CF3, NHCH3, CH2OCH3, and N(CH3).